ArticleFrontiers in pharmacology2018
Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations.
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children.British journal of clinical pharmacology · 2026Pooled it
- Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.Clinical pharmacokinetics · 2021Pooled it
- Vancomycin Therapeutic Drug Monitoring, Clinical Outcomes and Population Pharmacokinetic Model Evaluation in Neonates.Children (Basel, Switzerland) · 2026Article
- Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics.Microbiology spectrum · 2025Article
- Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models.The Journal of infectious diseases · 2025Article
- A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clinical pharmacokinetics · 2025Review
- External evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first-order equations to Bayesian-guided therapeutic monitoring.Pharmacotherapy · 2024Article
- Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.Clinical pharmacokinetics · 2024Article
- Effects of Sex Differences and Combined Use of Clozapine on Initial Dosage Optimization of Valproic Acid in Patients with Bipolar Disorder.Current pharmaceutical design · 2024Article
- Population pharmacokinetics of vancomycin in very low birth weight neonates.Frontiers in pediatrics · 2023Article
- Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation.European journal of hospital pharmacy : science and practice · 2022Article
- An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients.Clinical pharmacokinetics · 2022Review
- Analysis of a machine learning-based risk stratification scheme for acute kidney injury in vancomycin.Frontiers in pharmacology · 2022Article
- Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.European journal of drug metabolism and pharmacokinetics · 2021Article
- Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.BMC pharmacology & toxicology · 2021Article
- Population pharmacokinetics and dose optimization of vancomycin in neonates.Scientific reports · 2021Article
- Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight.Antimicrobial agents and chemotherapy · 2021Article
- External Evaluation of Vancomycin Population Pharmacokinetic Models at Two Clinical Centers.Frontiers in pharmacology · 2021Article
- Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function.Frontiers in pediatrics · 2021Article
- Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main goal of our study was to characterize the population pharmacokinetics of vancomycin in critically ill Chinese neonates to develop a pharmacokinetic model and investigate factors that have significant influences on the pharmacokinetics of vancomycin in this population. The study population consisted of 80 neonates in the neonatal intensive care unit (ICU) from which 165 trough and peak concentrations of vancomycin were obtained. Nonlinear mixed effect modeling was used to develop a population pharmacokinetic model for vancomycin. The stability and predictive ability of the final model were evaluated based on diagnostic plots, normalized prediction distribution errors and the bootstrap method. Serum creatinine (Scr) and body weight were significant covariates on the clearance of vancomycin. The average clearance was 0.309 L/h for a neonate with Scr of 23.3 μmol/L and body weight of 2.9 kg. No obvious ethnic differences in the clearance of vancomycin were found relative to the earlier studies of Caucasian neonates. Moreover, the established model indicated that in patients with a greater renal clearance status, especially Scr < 15 μmol/L, current guideline recommendations would likely not achieve therapeutic area under the concentration-time curve over 24 h/minimum inhibitory concentration (AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.